Regenerative Medicine Innovation and Development Forum: How the 'Era of Regeneration' Is Opening a New Door for the Industry

Medicine emerged to combat disease, and even in today’s era of advanced medical science, disease remains a significant factor affecting human survival and development. Currently, scientists are continuously researching and exploring to find the “ultimate weapon” against diseases. Regenerative medicine represents one important avenue of such exploration. In China, research in tissue regeneration and related fields has been gaining momentum in recent years, with many universities, hospitals, research institutions, and enterprises already engaged in this area. However, it is undeniable that the development of regenerative medicine in China is still in its very early stages; high-barrier technologies such as regenerated organs remain largely at the research level. The future advancement of regenerative medicine in China will depend on addressing core issues, including policy regulation, capital investment, product development, and coordination across the upstream and downstream sectors.

In this context, the organizers of the 7th Future Healthcare Top 100 Conference, with support from Huiding Capital, hosted the Regenerative Medicine Innovation and Development Forum. The event invited clinical experts, investment institutions, and leading enterprises to comprehensively discuss key issues in the field of regenerative medicine—including policies, innovation, products, and development challenges—from their respective perspectives.

2023 Future Healthcare Top 100 Conference, co-hosted by VB100, VCBeat, and Eggshell Research Institute, with strategic partnership support from Shanghai Zhangjiang Group, will be grandly held at the Shanghai Zhangjiang Science Hall from May 5–7, 2023. Led by Academician Robert Langer and IEEE scientists, nearly 500 industry leaders will convene for three main forums and 31 trending thematic sessions!